RXi Pharmaceuticals to Present Data on the Cellular Mechanism of RNAi Interference at Keystone Symposia's RNAi, MicroRNA, and Non-Coding RNA MeetingWORCESTER, Mass.--(BUSINESS WIRE)--Mar 20, 2008 - RXi Pharmaceuticals Corporation (Nasdaq: RXII), a leading company in RNA targeting, today announced that RXi scientists will present new data on the mechanism of RNAi compounds in cells at the premier academic RNAi meeting, Keystone Symposia's RNAi, MicroRNA, and Non-coding RNA, March 25-30, 2008. The experimental results of RXi's research indicate that RXi's proprietary rxRNA(TM) compounds are not cleaved by the dicer enzyme and that dicer processing is not required for the generation of extremely potent RNAi compounds.
"We are pleased that our scientists continue to contribute to the improved understanding of how RNAi interference works in the cell. The data presented has allowed us to refine the way in which we design RNAi compounds for potential therapeutic use, and further clarifies that our rxRNA(TM) compounds are distinct from competing traditional siRNA compounds," noted Tod Woolf, Ph.D., President and CEO.
Additionally, RXi co-founder and Scientific Advisory Board Chairman and Nobel Laureate, Craig Mello, Ph.D., and RXi co-founder and Scientific Advisory Board member, Greg Hannon, Ph.D., will deliver keynote addresses at the conference on Tuesday, March 25, 2008, during the Keynote session starting at 7:30 AM.
About Keystone Symposia's RNAi, MicroRNA, and Non-Coding RNA Meeting
The Symposia will be held at the Whistler Resort, Whistler, British Columbia where scientists will explore recent developments in understanding the molecular mechanisms and cell biology of RNA-based post-transcriptional silencing and for maintaining regions of silenced chromatin. Recent advances in harnessing RNA interference for genetic screening and therapeutic gene silencing will also be explored.
About RXi Pharmaceuticals Corporation
RXi Pharmaceuticals is a discovery-stage biopharmaceutical company pursuing the development and potential commercialization of proprietary therapeutics based on RNA interference (RNAi) for the treatment of human diseases. RXi Pharmaceuticals' rxRNA(TM) compounds are distinct from the siRNA compounds used by many other companies developing RNAi therapeutics and are believed by the Company, based on its internal research, to be up to 100x more active than conventional siRNA (depending on the target site), nuclease resistant and readily manufactured. RXi Pharmaceuticals believes it is well positioned to compete successfully in the RNAi-based therapeutics market with its accomplished scientific advisors, including Dr. Craig Mello, recipient of the 2006 Nobel Prize for his co-discovery of RNAi; a management team that is experienced in developing RNAi products; and a strong early intellectual property position.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about future expectations, plan and future development of RXi Pharmaceutical Corporation's products and technologies. These forward-looking statements about future expectations, plans and prospects of the development of RXi Pharmaceutical Corporation's products and technologies involve significant risks, uncertainties and assumptions, including the risk that the development of our RNAi-based therapeutics may be delayed or may not proceed as planned and we may not be able to complete development of any RNAi-based product, the risk that the FDA approval process may be delayed for any drugs that we develop, and the possibility that other companies or organizations may assert patent rights that prevent us from developing our products. Actual results may differ materially from those RXi Pharmaceuticals Corporation contemplated by these forward-looking statements. RXi Pharmaceuticals Corporation does not undertake to update any of these forward-looking statements to reflect a change in its views or events or circumstances that occur after the date of this release.
Donna Falcetti, 508-929-3615
Posted: March 2008